SLFN11 and paranasal sinus cancer: In nasal cavity and paranasal sinus cancers, the SLFN11-positive groups exhibited a significantly superior OS compared to the SLFN11-negative groups (5-year PFS: 86.4% vs. 74.8%, respectively, p = 0.031, Supplementary Figure 1B).